uniQure N.V. (QURE) Income Statement

The revenue trajectory is decelerating sharply, with the most recent quarter showing only $5.8M, a modest 11% sequential increase but still far below the $11.1M reported in 2024Q2. This volatility suggests that revenue is not recurring but tied to discrete milestones under the CSL Behring collaboration. The absence of product sales means growth durability is questionable, and investors should monitor whether new partnerships or AMT-130 commercialization can offset the structural decline.

The extreme volatility in gross margin—ranging from -78% to 94%—underscores that reported margins are not indicative of operational performance. The negative gross margin in 2026Q2 likely stems from cost overruns or write-offs associated with manufacturing, while the high margins in other quarters are due to low-cost milestone revenue. This suggests that as uniQure moves toward product sales, gross margins will normalize to levels more typical of gene therapy manufacturing, which could be significantly lower.

The lack of operating leverage is evident: even when revenue doubled in 2026Q1, operating losses widened sequentially, driven by increased R&D spending. SG&A has also crept up, from $9.4M in 2024Q4 to $20.1M in 2026Q1, suggesting overhead expansion ahead of potential commercialization. This implies that any revenue growth will not translate to profitability until the company either cuts costs significantly or achieves substantial product sales.

The consistency of R&D spending—despite revenue volatility—indicates a commitment to advancing the pipeline, but it also means the company is burning cash at a rate of roughly $40M per quarter. SG&A has shown some variability, but the overall cost structure is rigid, with little evidence of expense discipline. This suggests that management is prioritizing clinical progress over cost containment, which is typical for a late-stage biotech but heightens the need for successful regulatory outcomes.

This inflection point is critical because it provided upfront cash but sacrificed long-term income, leaving the company dependent on CSL Behring milestones and its own pipeline. The impact is visible in the revenue trajectory: pre-sale quarters like 2024Q2 had $11.1M revenue, while post-sale quarters have struggled to exceed $5.8M. This strategic choice suggests a need for immediate liquidity, which may indicate limited access to capital markets, and it has permanently altered the company's revenue base.